Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal CancerScott Kopetz, Josep Tabernero, Axel Grothey et al.|New England Journal of Medicine|2019Cited by 1.5k
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Patrick A. Ott, Sarina A. Piha‐Paul et al.|Journal of Thoracic Oncology|2019Cited by 437
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M. Henricks, Jan H.M. Schellens, Hans Gelderblom et al.|The Lancet Oncology|2018Cited by 419
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumoursMark T. J. van Bussel, Jan H.M. Schellens, Ahmad Awada et al.|British Journal of Cancer|2020Cited by 127
Clinical Experience with Aurora Kinase Inhibitors: A ReviewDavid S. Boss, Jan H.M. Schellens|The Oncologist|2009Cited by 103